ALLO Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Allogene Therapeutics Inc

Watchlist Manager

Watchlist

Price: 2 USD 1.01%

Market Cap: $690.3m

	Allogene Therapeutics Inc NASDAQ:ALLO	US
N	Netflix Inc F:NFC	US
N	Nomura Real Estate Master Fund Inc OTC:NMMRF	JP
H	Heidelberg Materials AG F:HEIU	DE
M	Merck KGaA DUS:MRK	DE
I	Ingevec SA SGO:INGEVEC	CL
O	Organon & Co XMUN:7XP	US
	Curro Holdings Ltd F:24P	ZA
	Capital Southwest Corp F:SFW	US
M	Mulberry Group PLC XBER:MUY	UK
K	Kingspan Group PLC F:KRX	IE
G	GoGold Resources Inc XMUN:GGD	CA

Profitability Summary

Allogene Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-2 893%

Negative 3Y Average Operating Margin

-390 183%

Operating Margin is Increasing

-188 658% > -2 893%

Negative Net Margin

-2 648%

Negative 3Y Average Net Margin

-393 226%

Net Margin is Increasing

-186 679% > -2 648%

Negative Free Cash Flow Margin

-2 211%

Negative 3Y Average Free Cash Flow Margin

-250 517%

Free Cash Flow Margin is Increasing

-127 095% > -2 211%

Negative ROE

-31%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-140%

ROIC is Increasing

-100% > -66%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.